Comparative Pharmacology
Head-to-head clinical analysis: AMRIX versus RALDESY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMRIX versus RALDESY.
AMRIX vs RALDESY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Centrally acting muscle relaxant; it is the R-enantiomer of baclofen. Agonist at GABA-B receptors in the spinal cord, leading to inhibition of monosynaptic and polysynaptic spinal reflexes, thereby reducing muscle spasticity.
Selective beta-3 adrenergic receptor agonist; relaxes detrusor smooth muscle during storage phase of urinary bladder fill cycle, increasing bladder capacity and reducing urgency.
15 mg orally once daily. May increase to 30 mg once daily if needed, after at least 1 week. Maximum 30 mg/day.
Intravenous: 1 mg/kg every 8 hours; maximum single dose 100 mg.
None Documented
None Documented
Terminal elimination half-life approximately 32 hours (range 28–40 hours); clinically relevant for once-daily dosing in chronic muscle spasm
4-6 hours in adults; prolonged to 8-12 hours in elderly or renal impairment (CrCl <30 mL/min)
Renal: approximately 40% as unchanged drug and metabolites; biliary/fecal: minimal; total clearance: 2.5 L/min
Primarily renal (85-90%) with 60% unchanged; biliary/fecal (10-15%)
Category C
Category C
Muscle Relaxant
Muscle Relaxant